<span item_type="fundamental" item_id="1adf52e8e93c59a600166beca588895d" counter_id="ST/US/CINGW" env="prod"></span><span item_type="announcement" item_id="551145942191507841" env="prod"></span><p>EPS: As of FY2025 Q2, the actual value is USD -1.09.</p><p>EBIT: As of FY2025 Q2, the actual value is USD -4.789 M.</p><p></p><h3>Segment Revenue</h3><ul><li><strong>Research and Development Expenses</strong>: Total R&amp;D expenses were $2.7 million for the three months ended June 30, 2025, an increase of $0.8 million or 43.6% from the three months ended June 30, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1862150/000164117225024744/form10-q.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Operating Loss</strong>: Operating loss was $4.7 million for the three months ended June 30, 2025, compared to $3.2 million for the same period in 2024, representing an increase of 45.0%.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1862150/000164117225024744/form10-q.htm"></span></li><li><strong>Net Loss</strong>: Net loss was $4.8 million for the three months ended June 30, 2025, compared to $3.2 million for the same period in 2024, representing an increase of 49.2%.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1862150/000164117225024744/form10-q.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Net Cash Used in Operating Activities</strong>: Net cash used in operating activities was $9.5 million for the six months ended June 30, 2025, compared to $10.5 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1862150/000164117225024744/form10-q.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Clinical Operations Costs</strong>: Clinical operations costs increased due to close-out and analytical activities required for NDA submission related to two Phase 3 studies for CTx-1301.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1862150/000164117225024744/form10-q.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: The company plans to advance commercialization efforts for CTx-1301 into early 2026, requiring approximately $1.5 million of additional capital.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1862150/000164117225024744/form10-q.htm"></span></li><li><strong>Non-Core Business</strong>: The company is evaluating strategic transactions to acquire or in-license additional products and product candidates to augment its internal development pipeline.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1862150/000164117225024744/form10-q.htm"></span></li></ul>

CINGULATE INC C/WTS 10/12/2026 (TO PUR COM) | 10-Q: FY2025 Q2 EPS: USD -1.09